Immunome (NASDAQ:IMNM) Shares Up 6.9%

Immunome, Inc. (NASDAQ:IMNM)’s share price shot up 6.9% during trading on Monday . The stock traded as high as $14.47 and last traded at $14.47. 158,510 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 775,945 shares. The stock had previously closed at $13.54.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IMNM shares. Piper Sandler cut their price objective on Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.00.

Immunome Stock Down 1.2 %

The business’s fifty day moving average is $14.09 and its two-hundred day moving average is $16.59. The stock has a market cap of $867.15 million, a price-to-earnings ratio of -1.90 and a beta of 1.77.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The business had revenue of $2.36 million during the quarter, compared to analyst estimates of $2.62 million. As a group, sell-side analysts expect that Immunome, Inc. will post -1.92 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime purchased 7,000 shares of Immunome stock in a transaction on Friday, August 16th. The shares were bought at an average price of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at $231,613.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was bought at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the acquisition, the director now directly owns 16,615 shares of the company’s stock, valued at approximately $231,613.10. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares in the company, valued at $222,880. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by insiders.

Institutional Trading of Immunome

Institutional investors have recently bought and sold shares of the business. EntryPoint Capital LLC increased its holdings in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after acquiring an additional 5,466 shares during the last quarter. Quest Partners LLC acquired a new position in Immunome in the second quarter valued at approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Immunome in the second quarter valued at approximately $97,000. Arizona State Retirement System raised its holdings in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares in the last quarter. Finally, AQR Capital Management LLC lifted its position in shares of Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after buying an additional 4,129 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.